Inhibition of TLR4/NF-κB pathway and inhibition of the NACHT, LRR, and PYD domain-containing protein 3 (NLRP3) inflammasome pathways may be one of the mechanisms for the treatment of AKI. The gene discussed is TLR4; the disease is acute kidney injury.